IQWiG General Methods 8.0: new version in force
IQWiG General Methods 8.0 entered force in December 2025, introducing new methods for hospital minimum volume standards and HTA assessment.
IQWiG (German HTA) · GermanyIQWiG (German HTA)
Regulation
Category
Type
Date
Colorectal cancer screening: No informative evidence for adjusting age limits or colonoscopy frequency
IQWiG finds insufficient evidence to change colorectal cancer screening age thresholds or colonoscopy intervals; recommends screening from age 50.
IQWiG (German HTA) · GermanyProblems in study implementation often affect patient-reported outcomes
IQWiG guidance on the importance of patient-reported outcomes in clinical trials and benefit assessments, illustrated by asciminib for chronic myeloid leukaemia.
IQWiG (German HTA) · GermanyJoint Clinical Assessments: a new chapter in European pharmaceutical policy
IQWiG and LSE researchers discuss the first Joint Clinical Assessment under the EU HTA Regulation and its implications for evidence generation.
IQWiG (German HTA) · GermanyAcupuncture for migraine prophylaxis: benefit limited to narrow therapeutic indication
IQWiG assessed manual acupuncture for migraine prophylaxis in adults, finding limited benefit compared with prevention medication and identifying evidence gaps.
IQWiG (German HTA) · GermanyIQWiG Autumn Symposium 2026: Focus on low-value care
Register now for the IQWiG Autumn Symposium on 20 November 2026 in Cologne! Cost pressures within the health care system are mounting, making the issue of low-value care all the more pressing: but how can medical serv...
IQWiG (German HTA) · GermanyExpert panel highlights opportunities for improving cancer studies
IQWiG publishes Cancer Medicines Forum workshop results proposing a roadmap for systematic implementation of cancer treatment optimization studies.
IQWiG (German HTA) · GermanyMinimum volume standards in hospitals: the first IQWiG projects have started
IQWiG received six commissions from the Federal Ministry of Health to develop scientific recommendations for minimum volume standards in hospital care under the German Hospital Reform Act 2024.
IQWiG (German HTA) · GermanyIQWiG assessment: linvoseltamab for relapsed or refractory multiple myeloma – unmet evidence need
IQWiG notes linvoseltamab received conditional marketing authorisation in April 2025 but comparative evidence is lacking until 2026.
IQWiG (German HTA) · GermanyCemiplimab for cutaneous squamous cell carcinoma: IQWiG benefit assessment – insufficient follow-up data
IQWiG finds insufficient long-term follow-up data in cemiplimab trials for cutaneous squamous cell carcinoma, echoing prior EMA concerns.
IQWiG (German HTA) · GermanyLecanemab for early-stage Alzheimer's disease: IQWiG benefit assessment concludes no added benefit
IQWiG's benefit assessment of lecanemab for early-stage Alzheimer's disease, based on previously unpublished manufacturer data, finds no proven added benefit over current standard care.
IQWiG (German HTA) · GermanyEU HTA Regulation: first joint clinical assessment completed (tovorafenib)
IQWiG completed the first joint clinical assessment under the new EU HTA process for tovorafenib in paediatric low-grade glioma, approved by the Member State Coordination Group.
IQWiG (German HTA) · GermanyTrastuzumab deruxtecan for gastric cancer: HTA assessment of considerable added benefit
IQWiG determines considerable added benefit of trastuzumab deruxtecan for HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma based on DESTINY-Gastric04 trial.
IQWiG (German HTA) · Germany
Showing 13 of 13 tracked updates
Health-tech only